Positive free cashflow and revenue growth were achieved, driven by strong Penthrox performance in Australia and Europe. Regulatory approval for paediatric use in the UK and EU expands the addressable market, with EBIT expected to improve modestly over FY25.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.